MET and neoplasm: Overexpression of MET is found in Tpl2-/- keratinocytes and cSCCs, and pharmacological inhibition of MET in Tpl2-/- mice decreased overall tumor burden by 60% and prevented malignant conversion of papillomas to cSCC [25].